How Much Will Retatrutide Cost?
Last updated: January 2026
Quick Answer
Retatrutide isn't yet approved. Based on tirzepatide pricing trends, brand-name retatrutide may cost $900-1,300/month without insurance. Compounded versions (if allowed after approval) could be $249-399/month, similar to tirzepatide today.
Understanding How Much Will Retatrutide Cost
Retatrutide isn't yet approved. Based on tirzepatide pricing trends, brand-name retatrutide may cost $900-1,300/month without insurance. Compounded versions (if allowed after approval) could be $249-399/month, similar to tirzepatide today.
GLP-1 medication pricing is one of the most important factors when choosing a treatment plan. Brand-name medications like Wegovy and Zepbound carry premium prices due to patent exclusivity, while compounded versions from licensed 503B pharmacies offer the same active ingredients at a fraction of the cost.
Price Comparison: Brand vs Compounded
Brand-name GLP-1 medications typically cost $900-1,500 per month without insurance coverage. Compounded versions through telehealth providers range from $149-449 per month, representing savings of 60-85%. Both options contain the same active pharmaceutical ingredients and are prescribed by licensed healthcare providers.
Ways to Reduce Your GLP-1 Costs
- Use HSA or FSA pre-tax dollars to save 20-40% on medication costs
- Compare pricing across multiple telehealth providers before committing
- Ask about manufacturer savings cards for brand-name medications
- Check if your insurance plan covers any GLP-1 medications
- Look for providers offering free consultations to avoid upfront costs
The cost of GLP-1 treatment should be weighed against the long-term health savings from treating obesity-related conditions. Studies show untreated obesity costs $1,861 more per year in medical expenses, making GLP-1 treatment a potentially cost-effective investment in your health.
Related Questions
When Will Retatrutide Be FDA Approved?
Eli Lilly launched the Phase 3 TRIUMPH program in 2024. FDA submission is expected in 2026, with potential approval in 2026-2027. Phase 3 results from the TRIUMPH-3 trial are expected in late 2025.
Will Insurance Cover Retatrutide?
Coverage will likely follow the tirzepatide pattern — covered with T2D diagnosis more readily than for obesity alone. Expect the same prior authorization challenges that affect current GLP-1s. Until approved, it's not prescribable or insurable.